Sinfonia Biotherapeutics is pioneering the development of novel, bioreactor-delivered drug treatments for familial & genetically-defined orphan neurodegenerative disorders within frontotemporal lobar dementia (FTD), Alzheimer’s and Parkinson’s disorders.

Just as cancer is composed of many different subtypes, we know dementia is as well. Thus, to succeed where others have failed in developing dementia treatments, we are developing breakthrough biologic therapies that target familial dementia subtypes with underlying disease mechanisms that are known.

To deliver our first-in-class disease-modifying therapies, we are employing our proprietary, implantable bioreactor device with cells engineered to manufacture single or multiple therapeutic factors locally within the brain.